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Modelling the dynamics of eBV 
transmission to inform a vaccine 
target product profile and future 
vaccination strategy
Lara Goscé1, Joanne R. Winter1, Graham s. taylor2, Joanna e. A. Lewis3 & Helen R. stagg1,4
epstein-Barr virus (eBV) is one of the most common human viruses and the cause of pathologies such 
as infectious mononucleosis (IM) and certain cancers. No vaccine against eBV infection currently exists, 
but such vaccines are in development. Knowledge of how eBV is transmitted at the population level is 
critical to the development of target product profiles (TPPs) for such vaccines and future vaccination 
strategies. We present the first mathematical model of EBV transmission, parameterised using data 
from England, and use it to compare hypothetical prophylactic vaccines with different characteristics 
and the impact of vaccinating different age groups. We found that vaccine duration had more impact 
than vaccine efficacy on modelled EBV and IM prevalence. The age group vaccinated also had an 
important effect: vaccinating at a younger age led to a greater reduction in seroprevalence but an 
increase in IM cases associated with delayed infection. Vaccination had impact on cancer incidence only 
in the long run, because in england most eBV-related cancers arise in later life. Durability of protection 
should be a key factor to prioritise in eBV vaccine development and included in vaccine tpps. these 
findings are timely and important for vaccine developers and policy-makers alike.
Epstein-Barr virus (EBV) is a gamma herpes virus and one of the most common human viruses; it is estimated 
that about 90% of the world’s adult population is infected1,2. Infection usually occurs in childhood, this occurs 
earlier in poorer settings, and it is often delayed until adolescence in developed countries3,4. Transmission is 
through saliva5 and infection is usually asymptomatic, but in some instances it may cause infectious mononucle-
osis (IM) or particular cancers such as Hodgkin’s lymphoma, Burkitt’s lymphoma, gastric cancer, nasopharyngeal 
carcinoma and diffuse large B cell lymphomas6,7. IM increases the risk of developing Hodgkin’s lymphoma in 
the ten year period after infection8. Immunocompromised individuals are at an increased risk of developing 
EBV-associated disease9.
It has been estimated that an EBV vaccine could prevent nearly 200,000 new malignancies each year, world-
wide10. EBV infection-preventing vaccines are currently in development10,11; a second generation EBV vaccine 
candidate is about to enter first-in-human trials12 and interest in the area continues to increase13. Consequently 
we have a window of opportunity to influence vaccine research and development. Target product profiles (TPPs) 
are planning tools that delineate a requisite set of attributes for new products to ensure that they are correctly pro-
filed for the needs of the environment in which they will operate. For example, the financial viability of a vaccine 
candidate at the population level depends upon how key vaccine characteristics such as efficacy and duration of 
protection affect both EBV transmission and disease progression, and how this varies in different settings. A per-
fect or near-perfect vaccine is highly unlikely - the only herpesviral vaccine currently licensed, VZV oka, is only 
85% effective when giving a single dose14- therefore there is a need a for a TPP specifying the characteristics of a 
potentially useful vaccine, and for the modelling tools to develop one.
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In this work we develop a simple compartmental model15 of EBV transmission and use it to test several 
hypothetical vaccines, varying the efficacy, duration of protection and age group targeted for vaccination. No 
dynamical model has ever previously been created to study the spread of EBV and the sequelae of infection. Our 
model is calibrated using data from England, but can easily be parameterised to other settings, making it globally 
informative.
Methods
Model. We created a compartmental model (Fig. 1) for the spread of EBV, described using ordinary differen-
tial equations (Appendix). The model is calibrated to data from England but, given its simple structure, can easily 
be parameterised to study EBV transmission in other settings.
In our model, the population is divided into a single susceptible compartment S and three infected compart-
ments: asymptomatic-EBV infected I, IM cases DIM and cancer cases DC (Fig. 1a). All individuals are born sus-
ceptible to the infection, entering compartment S. Susceptible individuals become infected at a rate that depends 
on the rate of contact with infectious individuals and the per-contact transmission probability, both of which are 
age dependent. When susceptible individuals become infected, they have a probability p of developing IM and 
moving to the IM compartment DIM. Otherwise, they move to the asymptomatic EBV-infected compartment I. 
Individuals recovering from IM (but not from EBV infection) also flow into compartment I. EBV infection is 
lifelong and cannot be cleared immunologically or by treatment, so infected people remain in compartment I. 
From here they may develop one of the most common EBV-associated cancers: Hodgkin’s lymphoma, Burkitt’s 
lymphoma, gastric cancer or nasopharyngeal carcinoma, and move to compartment DC. Individuals can leave 
this compartment through death or recovery; in the latter case, individuals move back to the EBV-infected com-
partment I. For simplicity, all cancers are included in a single compartment and IM is not considered as a possible 
risk factor for cancer. All individuals, at any age and any stage of infection, are affected by natural mortality. Age 
heterogeneity was included in the model by dividing the population into age groups, within which individuals’ 
ages were uniformly distributed.
To test possible vaccination strategies, we modified the model by adding an extra compartment for vaccinated 
individuals (Fig. 1b). Susceptible individuals are vaccinated at a rate ν and move to the vaccinated compartment 
V. All uninfected individuals who are not protected by vaccination remain in the susceptible compartment S. 
Vaccinated individuals can still be infected and develop IM, depending on the efficacy of the vaccine φ. Over time 
vaccine protection wears off at a rate d, and individuals return to compartment S. We modelled different vaccine 
efficacies and durations, and proposed different target age groups for vaccination.
parameters. We identified the following age groups of interest: 0–4 years old, 5–11 years old, 12–18 years old, 
19–24 years old and 25+ years old. These groups were chosen according to the UK education system and repre-
sent the preschool years, primary school, secondary school, tertiary education and later years, respectively. EBV 
seroprevalence was estimated in 12–18 and 19–24-year-olds using stored blood samples from the Health Survey 
Figure 1. (a) EBV model: Schematic describing the spread of EBV in a population. All individuals are born 
susceptible S at rate b. They become infected with force of infection λ. Once infected, they have a probability 
p of developing IM and move to the IM compartment DIM, where they remain until they recover, at rate ρM. 
Post-IM, individuals move to the EBV-infected compartment I. Infected individuals who do not develop IM 
also sit here. Unless a person develops cancer and moves to compartment DC at rate q, they remain in I for life. 
From DC people can either die, at death rate μc which is higher than the natural death rate μ, or they can recover 
at rate ρc and move back to compartment I. (b) EBV model with vaccination: Schematic describing the spread of 
EBV in a population, including the possibility of vaccination. All individuals are born susceptible S. A fraction 
of them are vaccinated pre-infection at a rate ν and move to the vaccinated compartment V where they may 
nonetheless be infected with a force of infection λ which is reduced according to the vaccine efficacy φ. Vaccine 
protection is lost with time, and individuals move back to the susceptible compartment at rate d.
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for England (HSE)16, an annual cross-sectional survey. The processing of samples from the HSE was approved by 
the University College London Research Ethics Committee (5683/002). The HSE obtained informed written con-
sent for blood samples to be collected and stored for future analyses. Stratifying by sex and age, 732 samples were 
randomly selected from individuals aged 11–24 years who participated in the 2002 HSE4. Samples were tested for 
EBV antibody, and the results used to calculate EBV prevalence by age group (Table 1). For younger and older 
individuals, published studies, were used3,17–19.
Natality and mortality data were sourced from the Office for National Statistics (ONS)20 for the years 1990 
(the mid-point between the birth of the oldest individuals in the HSE sample) to 2016 (the latest year for which 
demographic data were available) Table 2. We assumed that levels of infections within each age group were at 
equilibrium, since EBV is not an emerging infection but has co-evolved with humans21.
The proportions of EBV infections in different age groups that progressed to IM were calculated by the ratio 
of IM incidence22 and EBV incidence. Similarly, the rate of progression to cancer was calculated from data on 
cancer incidence in England, sourced from the ONS and Cancer Research UK (CRUK)20,23. Only the fraction of 
cases that were EBV-associated were considered24–26. Cancer recovery and death rates were calculated by fitting 
an exponential decay function to 1- and 5-year survival rates23. Both IM and cancer rates were calculated from 
the most recent data available (2012 and 2015, respectively) to ensure our model was up-to-date to inform future 
vaccine policy. The meanings and sources of the parameters are summarised in Table 2. The model was calibrated 
to EBV prevalence data by least-squares fitting: the residual distance between model output and data was mini-
mised by varying each age group’s transmission parameter β.
Starting from a ’baseline’ vaccine with perfect efficacy and lifelong duration, we reduced both efficacy and 
duration to study more realistic scenarios. Three different levels of efficacy were tested (60%, 80% and 100%), and 
four average durations (5 years, 10 years, 20 years and lifelong).
The systems of equations were coded using Matlab2016b. The code used for simulations and producing plots 
is available on request.
Results
Current eBV trends in the absence of a vaccine. Initially we modelled EBV infection, IM and cancers 
by age group in the absence of a vaccine. Figure 2a shows simulated EBV prevalence by age group over the 27 
years of model running time (1990–2016). Around 50% of individuals were infected before reaching 5 years of 
age. Seroprevalence then remained relatively stable in the 5–11 age group at ∼55% and increased slightly in the 
12–18 age group, to 65–70%. High levels of infection were seen in the 19–24 age group (∼88%) and in over-25s 
(∼90%).
Figures 2b,c show simulated numbers of IM cases and EBV-associated cancers by age group, respectively. 
Figure 2b shows that the highest numbers of IM cases are in teenagers (12–18) and young adults (19–24); only a 
very limited number of cases occur in the youngest age groups. Almost all cancer cases were observed in the over-
25s, which fits with the known age distribution of the EBV-associated cancers most commonly found in England.






Table 1. EBV prevalence in England, by age group.
Parameter Description Value Source
Births (b) Number of people born in England between 1990–2016 Data 20
Deaths (μ) Natural deaths per age group Data 20
Probability of IM by age (p) Likelihood of progression to IM after EBV infection calculated per age group from IM incidence in Scotland
0.003; 0.040; 0.149; 0.079; 
0.843 calibrated from data
22
IM recovery rate (ρM)
Rate of recovery from IM assuming 6 months symptoms 
duration after clinical onset 2
32
Probability of acquiring cancer (q) Likelihood of developing cancer following EBV infection calculated by age group from 2015 ONS cancer data Data
20
Cancer recovery rates (ρc)
EBV associated cancer recovery rates calculated by fitting 
an exponential decay to 1 and 5 years survival rate
0.6420 0.8097 0.8895 0.8060 
0.5309 fitted from data
23
Cancer death rate (μc)
EBV associated cancer death rates calculated by fitting an 
exponential decay to 1 and 5 years survival rates
0 0.0964 0.1247 0.0488 
0.3819 fitted from data
23
Vaccine duration rate (by strategy) (d) Rate of return from “vaccinated” (V) to “susceptible” (S) compartment 0.2; 0.1; 0.05; 0
Vaccine efficacy (by strategy) (φ) Proportion of “vaccinated” compartment (V) protected by vaccine 1; 0.8; 0.6
Table 2. Table of parameters.
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Impact of vaccination on eBV infection. Having modelled the current epidemiological landscape, we 
examined the effects of theoretical vaccines and vaccination strategies, starting with the perfect scenario of 100% 
efficacy and lifelong duration. Figure 3 (bottom-right panel) shows that with a ’perfect’ vaccine, vaccination in the 
0–4 age group has the highest overall impact on the whole population, substantially reducing EBV seroprevalence 
in all age groups.
We then varied vaccine efficacy (60%, 80%, 100%) and vaccine duration (5 years, 10 years, 20 years, lifelong) 
to investigate the effect of less effective and less durable vaccines. Overall, the impact of vaccine duration on EBV 
seroprevalence was greater than that of vaccine efficacy. Reducing the efficacy of the vaccine from 100% to 60% 
limited the success of the vaccine in controlling infection, regardless of the duration of protection. In contrast, 
at efficacies above 60% the impact of increasing the vaccine duration was greater than improving the efficacy. 
Specifically, Fig. 3 shows that the difference in the number of EBV infections averted with a vaccine of lifelong 
duration versus one of 5 years’ duration is considerably higher than the difference in number of infections averted 
when improving efficacy from 80% to 100%, particularly in older age groups. The choice of the age group to vacci-
nate is of considerable importance; the younger the age group targeted (0–4 age group), the greater the reduction 
in EBV seroprevalence observed in the whole population.
Impact of vaccination on IM disease. In the previous section, we highlighted the importance of vac-
cine duration in reducing EBV prevalence. When analysing the number of prevalent IM cases, this feature is 
Figure 2. Simulated EBV prevalence, number of prevalent IM cases and EBV-associated cancers, by age, 
England 1990–2016. The five age groups are 0–4 (green), 5–11 (cyan), 12–18 (blue), 19–24 (pink) and 25+ 
(yellow). Point markers indicate the EBV prevalence data used for calibration, with 95% confidence intervals 
shown by the error bars Table 1.
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even more important because short duration vaccines, by delaying infection with EBV, could potentially lead 
to an increase in IM cases (Fig. 4). The ’perfect’ vaccine (Fig. 4; bottom-right panel) has a high impact, reducing 
the number of IM cases. Its lifelong duration ensures that, even if vaccinated at a young age, individuals have a 
lifelong protection from disease, especially during the ages when the probability of IM is higher (Fig. 4). This is 
not the case for less durable and/or less effective vaccines. A combination of high efficacy and short duration of 
protection creates the most problematic results. The highest efficacies ensure that most vaccinated individuals are 
protected throughout the duration of the vaccine, but afterwards they may lose protection and become suscep-
tible to EBV at an age when the probability of IM is higher. This outcome depends strongly on the age group tar-
geted. As described above, vaccinating younger individuals, even with an imperfect vaccine (i.e. efficacy <100% 
and duration less than lifelong) has the greatest impact in reducing EBV prevalence in the population. There is, 
however, the opposite effect on the numbers of IM cases. If the duration of the vaccine is not long enough, indi-
viduals vaccinated in the 0–4 group eventually return to the susceptible compartment during adolescence, when 
the probability of IM after EBV infection is higher than the age at which they were vaccinated. Consequently, 
we see a rise of IM cases in older individuals, particularly in the long run. Similar, but less dramatic, results arise 
when vaccinating in the 5–11 age group (Appendix, Fig. 7), where a vaccine with a duration of at least 10 years 
would be needed to reduce IM cases in all age groups. The best possible scenarios arise when vaccinating individ-
uals in the 12–18 age group, where IM cases are reduced in any of the scenarios analysed.
Impact of vaccination on eBV-associated cancers. Our results show that the impact of EBV vaccina-
tion in any of the age groups on related cancers is very small in the short term, even with a perfect vaccine (Fig. 5). 
This is because the vast majority of cancer cases arise later in life and thus our model does not fully capture them 
over its 27 year running period. To get a measure of the possible impact of vaccination on EBV-associated can-
cers in the long run, we projected our modelling results of the number of cancers in the 25+ age group to 2090, 
assuming constant average birth and death rates (Fig. 6). The increasing number of cancer cases is a consequence 
of population growth. The scenarios analysed show the importance of vaccine duration in the reduction of cancer 
prevalence, as both vaccine efficacy and age of vaccination have limited impact when the duration of protection is 
short. If duration of protection is limited there may be a need for a second dose of vaccine.
Since cancers develop at any point after primary infection, the best strategy in the long run would be the one 
that offers the maximal reduction of EBV infections i.e. vaccination at 6 months with a long-duration vaccine. If 
a vaccine has a short duration of protection, vaccinating the oldest age group could be seen as a sensible strategy; 
however this is ineffective because infection generally occurs before this age.
Discussion
In this study we created the first compartmental model describing EBV transmission, and calibrated it to data 
from England. Although EBV infection-preventing (prophylactic) vaccines are not currently available, many 
are under development and thus studies such as ours have a window of opportunity in which to inform vaccine 
development and future deployment strategies. In our model, we therefore studied different vaccination strategies 
(targeting different age groups) in the context of varying both vaccine duration and efficacy.
Our study clearly indicates the importance of the duration of protection offered by future vaccines, which 
has a higher impact on EBV seroprevalence than vaccine efficacy of the vaccine. Duration of protection should 
therefore be a core component of the TPP for anti-infection EBV vaccines. Vaccines with poor efficacy (below 
about 60%) have no significant impact on population prevalence, but for vaccines with better efficacy, a greater 
Figure 3. Prevalence of EBV infection, by age group, vaccine duration and efficacy. Results when targeting 
different age groups are shown in each figure using three dashed lines: (−) when vaccinating individuals in the 
0–4 age group, (:) when vaccinating in the 5–11 age group and (−) when vaccinating in the 12–18 age group. 
These results are compared with EBV prevalence levels when no vaccination is implemented (solid lines).
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reduction in EBV seroprevalence is achieved by lengthening the duration of protection than by further improving 
efficacy. The duration of vaccine protection also has an important impact on the prevalence of IM disease, as vac-
cines with a short duration may wear off during adolescence, when the probability of IM is highest. Meanwhile, 
any type of vaccination has little population-level impact on EBV-associated cancer rates within the time span of 
our model due to the age distribution of EBV-related cancers in high-income countries such as England. A signif-
icant impact of vaccination on cancer rates would only be observable in the long term. In low-income countries 
where, for example, Burkitt’s lymphoma is more common, we would expect the impact of the vaccine on cancer 
rates to be more apparent at an earlier stage, as originally proposed by Epstein27. Our study was limited by the 
lack of data to inform some of the model parameters. For example, we do not know the impact on the likelihood 
of developing IM if infection with EBV is delayed (by vaccination) beyond an individual’s mid-twenties. The 
rate could remain high, as we see in teenagers in England, or could revert back to that observed in the youngest 
age groups. Table 3 discusses some areas of uncertainty and proposes potential study designs. Future modelling 
work could use a Bayesian evidence synthesis approach, combining the mathematical model we present here with 
data from several study designs, to obtain better parameter estimates and predictions comparing vaccination 
strategies.
Figure 4. Number of prevalent IM cases, by age group, vaccine duration and efficacy. Results when targeting 
different age groups are shown in each figure using three dashed lines: (−.) when vaccinating individuals in the 
0–4 age group, (:) when vaccinating in the 5–11 age group and (−) when vaccinating in the 12–18 age group. 
These results are compared with numbers of IM cases when no vaccination is implemented (solid lines).
Figure 5. Numbers of prevalent EBV associated cancers, by age group, vaccine duration and efficacy. Results 
when targeting different age groups are shown in each figure using three dashed lines: (−.) when vaccinating 
individuals in the 0–4 age group, (:) when vaccinating in the 5–11 age group and (−) when vaccinating in the 
12–18 age group. These results are compared with cancer prevalence levels when no vaccination is implemented 
(solid lines).
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Varicella-zoster virus (VZV), currently the only herpes virus with a licensed vaccine, provides some clues as 
to the characteristics of potential future EBV vaccine. One dose of VZV vaccine is 85% effective at preventing any 
form of varicella, while two doses are 98% effective14. The duration of vaccine protection is not well understood; 
some studies have shown that most children vaccinated against VZV are protected for at least eight (with one 
dose28) to ten (with two doses29) years, and if disease presents later they show only mild symptoms. In the UK var-
icella vaccination is not part of the routine childhood vaccination programme because delaying infection could 
increase the risk of (severe) disease in adults30. By comparison, the VZV vaccine is given to individuals over the 
age of 70, to prevent reactivation-associated disease (shingles). The bimodal age distribution of VZV-associated 
disease thus has critical implications. If a reactivation-preventing EBV vaccine was also developed it could poten-
tially be administered to older, already EBV-infected people to reduce virus reactivation which could potentially 
also reduce the risk of cancer development.
In any setting, from a policy-making perspective, the best possible EBV vaccination strategy would be to vac-
cinate all babies once they lose their maternal antibody protection (around 6 months old) if the vaccine has good 
efficacy (≥80%) and long protection (>20 years). This would ensure the greatest reduction of EBV infections, 
IM cases and cancers in the long run. However, if the vaccine is protective only for a short time, vaccination at 12 
years of age would not substantially affect the prevalence of EBV in the population but would reduce the number 
of IM cases. Another advantage of vaccination at six months old is that all babies could be vaccinated without 
needing to test for prior infection. Such testing could be required if teenagers were vaccinated, as more than half 
would already be infected by their twelfth birthday. Such testing would not necessarily preclude the development 
of a vaccination programme, as demonstrated by the tuberculosis vaccine BCG, where pre-screening was until 
recently performed prior to vaccination. An alternative would be to simply vaccinate all teenagers without testing 
for prior EBV infection, although this would clearly increase overall costs of vaccine supply. Both scenarios would 
need to be considered when making the economic case for vaccination. Further economic evaluation studies are 
needed to inform the cost of future vaccines in order to select the most cost-effective strategy. Because IM does 
Figure 6. Projected numbers of prevalent EBV associated cancers in the 25+ age group. Lifelong and 10 years 
vaccine duration were analysed, with varying efficacy of 100% (magenta), 80% (blue) and 60% (cyan), no 
vaccination (yellow) was also included. Modelling results were projected to 2090 assuming constant average 
birth and death rates.
Area of uncertainty Explanation Potential study design
Granular EBV prevalence data by age EBV prevalence data is limited and often outdated. Cross-sectional seroprevalence study including participants of all ages.
Likelihood of EBV transmission 
following contact between susceptible 
and infectious individuals
Infected individuals are not constantly and 
uniformly infectious. Seasonality and virus 
shedding mechanisms play a role in the 
transmission.
Virus shedding analysis could inform 
individual-level models and give important 
information on virus transmission.
Likelihood of progressing to infectious 
mononucleosis if infection by EBV is 
delayed
Although the likelihood of progression to IM is 
reasonably well documented for all age groups, it 
is unknown what will happen if age at infection is 
delayed due to vaccination.
Prospective cohort study of newly infected 
individuals in older age groups. Due to 
the high prevalence of EBV globally this 
may only be feasible once an infection-
preventing vaccine is released.
Cost-effectiveness of different 
vaccination strategies
Economic evaluation studies are essential to analyse 
the feasibility of a vaccination program in real 
settings.
Cost-effectiveness study to calculate 
threshold values for the cost of EBV vaccine 
for different vaccination strategies.
Table 3. Areas of uncertainty and potential study designs.
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not cause mortality, it could be argued that it is acceptable to have a higher number of IM cases in order to reduce 
EBV seroprevalence and, consequently, the incidence of EBV-associated cancer in the population. In that case, 
vaccinating babies with a vaccine with a shorter duration of protection may still be an optimal strategy. We should 
also consider, however, that our model does not account for the potential role of IM as a risk factor for cancers 
such as Hodgkin’s lymphoma7,31. This means that, depending on the prevalence of different cancers in the country 
of interest, it may be more important to reduce the incidence of IM in the population than EBV seroprevalence, 
from both an epidemiological and an economical point of view. Thus, vaccination at 12 years old could be a 
feasible strategy if a vaccine with a limited duration was developed. Future work could focus on studying other 
countries’ EBV epidemiology. By taking into account local EBV seroprevalence, IM incidence, demographic and 
cancer data, the model can easily be parametrised to different settings to address suitable vaccination strategies.
In summary, we have described the first model of EBV transmission and used it to determine the impact of 
hypothetical infection-preventing vaccines with different characteristics. Our work, showing that the duration 
of vaccine protection will be the key determinant of a successful prophylactic EBV vaccine and the need for this 
characteristic to be included in a TPP, has important implications for three distinct areas of the drug development 
pathway. First, at the basic research stage, strategies able to elicit durable protection should be prioritised. Second, 
for efficacy testing where in vivo studies and subsequent first-in-human trials should be designed to measure if 
protection is sustained. Third, for policy makers where durability of vaccine-mediated protection should be a key 
factor informing the decision whether to implement a potential vaccine for widespread use in the population.
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